241 related articles for article (PubMed ID: 15121756)
1. 15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; Li ML
Jpn J Clin Oncol; 2004 Apr; 34(4):202-5. PubMed ID: 15121756
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder.
Hara I; Miyake H; Takechi Y; Eto H; Gotoh A; Fujisawa M; Okada H; Arakawa S; Kamidono S;
Int J Urol; 2003 Jan; 10(1):19-24. PubMed ID: 12534921
[TBL] [Abstract][Full Text] [Related]
3. Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer.
Bono AV; Lovisolo JA; Saredi G
Eur Urol; 2000 Apr; 37(4):478-83. PubMed ID: 10765080
[TBL] [Abstract][Full Text] [Related]
4. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.
Halachmi S; Moskovitz B; Maffezzini M; Conti G; Verweij F; Kedar D; Sandri SD; Nativ O; Colombo R
Urol Oncol; 2011; 29(3):259-64. PubMed ID: 19395285
[TBL] [Abstract][Full Text] [Related]
5. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
[TBL] [Abstract][Full Text] [Related]
6. [Conservative treatment of high-risk (T1G3) transitional carcinoma].
Catanzaro F; Torelli F; Catanzaro M; Cappellano F; Pizzoccaro M; Baruffi M; Sironi D; Pozzoli GL
Arch Ital Urol Androl; 1996 Feb; 68(1):21-4. PubMed ID: 8664915
[TBL] [Abstract][Full Text] [Related]
7. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
[TBL] [Abstract][Full Text] [Related]
8. Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy.
Palou-Redorta J; Solsona E; Angulo J; Fernández JM; Madero R; Unda M; Martínez-Piñeiro JA; Portillo J; Chantada V; Moyano JL
Actas Urol Esp; 2016; 40(6):370-7. PubMed ID: 26922518
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer.
Witjes JA; Dalbagni G; Karnes RJ; Shariat S; Joniau S; Palou J; Serretta V; Larré S; di Stasi S; Colombo R; Babjuk M; Malmström PU; Malats N; Irani J; Baniel J; Cai T; Cha E; Ardelt P; Varkarakis J; Bartoletti R; Spahn M; Pisano F; Gontero P; Sylvester R
Urol Oncol; 2016 Nov; 34(11):484.e19-484.e25. PubMed ID: 27639776
[TBL] [Abstract][Full Text] [Related]
10. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
[TBL] [Abstract][Full Text] [Related]
11. Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up.
Hurle R; Losa A; Manzetti A; Lembo A
Urology; 1999 Aug; 54(2):258-63. PubMed ID: 10443721
[TBL] [Abstract][Full Text] [Related]
12. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
[TBL] [Abstract][Full Text] [Related]
13. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
14. Delayed Cystectomy for T1G3 Transitional Cell Carcinoma (TCC) of the Urinary Bladder, NCI Retrospective Case Series.
Fakhr I; El-Hossieny H; Salama A
J Egypt Natl Canc Inst; 2008 Dec; 20(4):387-94. PubMed ID: 20571597
[TBL] [Abstract][Full Text] [Related]
15. Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours.
Patard JJ; Rodriguez A; Leray E; Rioux-Leclercq N; Guillé F; Lobel B
Eur Urol; 2002 Jun; 41(6):635-41; discussion 642. PubMed ID: 12074781
[TBL] [Abstract][Full Text] [Related]
16. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
[TBL] [Abstract][Full Text] [Related]
17. 17-year follow-up of a randomized prospective controlled trial of adjuvant intravesical doxorubicin in the treatment of superficial bladder cancer.
Cheng CW; Chan PS; Chan LW; Chan CK; Ng CF; Lai MM
Int Braz J Urol; 2005; 31(3):204-11. PubMed ID: 15992422
[TBL] [Abstract][Full Text] [Related]
18. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
19. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
[TBL] [Abstract][Full Text] [Related]
20. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
Fujimoto K; Chihara Y; Kondo H; Hirao Y
Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
